Drug Profile
Research programme: antiplatelet therapeutic - Life Science Entrepreneurs
Alternative Names: NmCLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Unknown
- Developer Life Science Entrepreneurs
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Spain
- 05 Nov 2012 Preclinical trials in Cardiovascular disorders in Spain (unspecified route)